GFR Estimating Equations and Liver Disease

Advances in Chronic Kidney Disease

Volumn 22, Issue 5, 2015, Pages 337-342

  Beben, Tomasz ^a   Rifkin, Dena E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cirrhosis; Estimated GFR

Indexed keywords

ALBUMIN; BILIRUBIN; BIOLOGICAL MARKER; CREATININE; CYSTATIN C;

ACCURACY; BILIRUBIN BLOOD LEVEL; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE SEVERITY; GLOMERULUS FILTRATION RATE; HUMAN; INTERMETHOD COMPARISON; ISOTOPE DILUTION ASSAY; LIVER DISEASE; MASS SPECTROMETRY; PATIENT CARE; PATIENT IDENTIFICATION; PATIENT SELECTION; PRIORITY JOURNAL; RENOGRAPHY; REVIEW; ADVERSE EFFECTS; BLOOD; ELECTIVE SURGERY; FEMALE; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; PATHOPHYSIOLOGY; PHYSIOLOGY; PREOPERATIVE CARE; PROCEDURES; PROGNOSIS; SENSITIVITY AND SPECIFICITY; STANDARDS; TRANSPLANTATION; TREATMENT OUTCOME; TRENDS;

BIOMARKERS; CREATININE; CYSTATIN C; ELECTIVE SURGICAL PROCEDURES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; PREOPERATIVE CARE; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TISSUE AND ORGAN PROCUREMENT; TREATMENT OUTCOME;

EID: 84983143225     PISSN: 15485595     EISSN: 15485609     Source Type: Journal    
DOI: 10.1053/j.ackd.2015.05.003     Document Type: Review

References (52)

1. Davis C.L., Gonwa T.A., Wilkinson A.H. Pathophysiology of renal disease associated with liver disorders: implications for liver transplantation. Part I. Liver Transpl 2002, 8(2):91-109.
2. Davenport A., Cholongitas E., Xirouchakis E., Burroughs A.K. Pitfalls in assessing renal function in patients with cirrhosis-potential inequity for access to treatment of hepatorenal failure and liver transplantation. Nephrol Dial Transplant 2011, 26(9):2735-2742.
3. Rognant N., Lemoine S. Evaluation of renal function in patients with cirrhosis: where are we now?. World J Gastroenterol 2014, 20(10):2533-2541.
4. Wyss M., Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiol Rev 2000, 80(3):1107-1213.
5. Forbes G.B., Bruining G.J. Urinary creatinine excretion and lean body mass. Am J Clin Nutr 1976, 29(12):1359-1366.
6. Papadakis M.A., Arieff A.I. Unpredictability of clinical evaluation of renal function in cirrhosis. Am J Med 1987, 82(5):945-952.
7. Caregaro L., Menon F., Angeli P., et al. Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis. Arch Intern Med 1994, 154(2):201-205.
8. Pirlich M., Schütz T., Spachos T., et al. Bioelectrical impedance analysis is a useful bedside technique to assess malnutrition in cirrhotic patients with and without ascites. Hepatology 2000, 32(6):1208-1215.
9. Kuster N., Bargnoux A.-S., Pageaux G.-P., Cristol J.-P. Limitations of compensated Jaffe creatinine assays in cirrhotic patients. Clin Biochem 2012, 45(4-5):320-325.
10. Greenberg N., Roberts W.L., Bachmann L.M., et al. Specificity characteristics of 7 commercial creatinine measurement procedures by enzymatic and jaffe method principles. Clin Chem 2012, 58(2):391-401.
11. Owen L.J., Keevil B.G. Does bilirubin cause interference in Roche creatinine methods?. Clin Chem 2007, 53(2):370-371.
12. Cholongitas E., Marelli L., Kerry A., et al. Different methods of creatinine measurement significantly affect MELD scores. Liver Transpl 2007, 13(4):523-529.
13. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130(6):461-470.
14. Gonwa T.A., Jennings L., Mai M.L., Stark P.C., Levey A.S., Klintmalm G.B. Estimation of glomerular filtration rates before and after orthotopic liver transplantation: evaluation of current equations. Liver Transpl 2004, 10(2):301-309.
15. Francoz C., Glotz D., Moreau R., Durand F. The evaluation of renal function and disease in patients with cirrhosis. J Hepatol 2010, 52(4):605-613.
16. Pöge U., Gerhardt T., Stoffel-Wagner B., Klehr H.U., Sauerbruch T., Woitas R.P. Calculation of glomerular filtration rate based on Cystatin C in cirrhotic patients. Nephrol Dial Transplant 2006, 21(3):660-664.
17. MacAulay J., Thompson K., Kiberd B.A., Barnes D.C., Peltekian K.M. Serum creatinine in patients with advanced liver disease is of limited value for identification of moderate renal dysfunction: are the equations for estimating renal function better?. Can J Gastroenterol 2006, 20(8):521-526.
18. Levey A.S., Stevens L.A., Schmid C.H., et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009, 150(9):604-612.
19. Francoz C., Prié D., Abdelrazek W., et al. Inaccuracies of creatinine and creatinine-based equations in candidates for liver transplantation with low creatinine: impact on the model for end-stage liver disease score. Liver Transpl 2010, 16(10):1169-1177.
20. De Souza V., Hadj-Aissa A., Dolomanova O., et al. Creatinine- versus cystatine C-based equations in assessing the renal function of candidates for liver transplantation with cirrhosis. Hepatology 2014, 59(4):1522-1531.
21. Gerhardt T., Pöge U., Stoffel-Wagner B., Palmedo H., Sauerbruch T., Woitas R.P. Creatinine-based glomerular filtration rate estimation in patients with liver disease: the new Chronic Kidney Disease Epidemiology Collaboration equation is not better. Eur J Gastroenterol Hepatol 2011, 23(11):969-973.
22. Roy L., Legault L., Pomier-Layrargues G. Glomerular filtration rate measurement in cirrhotic patients with renal failure. Clin Nephrol 1998, 50(6):342-346.
23. Orlando R., Mussap M., Plebani M., et al. Diagnostic value of plasma cystatin C as a glomerular filtration marker in decompensated liver cirrhosis. Clin Chem 2002, 48(6):850-858.
24. Levey A.S., Perrone R.D., Madias N.E. Serum creatinine and renal function. Annu Rev Med 1988, 39:465-490.
25. Orlando R., Floreani M., Padrini R., Palatini P. Evaluation of measured and calculated creatinine clearances as glomerular filtration markers in different stages of liver cirrhosis. Clin Nephrol 1999, 51(6):341-347.
26. DeSanto N.G., Anastasio P., Loguercio C., et al. Creatinine clearance: an inadequate marker of renal filtration in patients with early posthepatitic cirrhosis (Child A) without fluid retention and muscle wasting. Nephron 1995, 70(4):421-424.
27. Demirtaş S., Bozbaş A., Akbay A., Yavuz Y., Karaca L. Diagnostic value of serum cystatin C for evaluation of hepatorenal syndrome. Clin Chim Acta 2001, 311(2):81-89.
28. Proulx N.L., Akbari A., Garg A.X., Rostom A., Jaffey J., Clark H.D. Measured creatinine clearance from timed urine collections substantially overestimates glomerular filtration rate in patients with liver cirrhosis: a systematic review and individual patient meta-analysis. Nephrol Dial Transplant 2005, 20(8):1617-1622.
29. Kim D.J., Kang H.S., Choi H.S., et al. Serum cystatin C level is a useful marker for the evaluation of renal function in patients with cirrhotic ascites and normal serum creatinine levels. Korean J Hepatol 2011, 17(2):130-138.
30. Plebani M., Dall'Amico R., Mussap M., et al. Is serum cystatin C a sensitive marker of glomerular filtration rate (GFR)? A preliminary study on renal transplant patients. Ren Fail 1998, 20(2):303-309.
31. Chew J.S., Saleem M., Florkowski C.M., George P.M. Cystatin C-a paradigm of evidence based laboratory medicine. Clin Biochem Rev 2008, 29(2):47-62.
32. Inker L.A., Okparavero A. Cystatin C as a marker of glomerular filtration rate: prospects and limitations. Curr Opin Nephrol Hypertens 2011, 20(6):631-639.
33. Hoek F.J., Kemperman F.A.W., Krediet R.T. A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transplant 2003, 18(10):2024-2031.
34. Dharnidharka V.R., Kwon C., Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002, 40(2):221-226.
35. Shlipak M.G., Matsushita K., Ärnlöv J., et al. Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med 2013, 369(10):932-943.
36. Woitas R.P., Stoffel-Wagner B., Flommersfeld S., et al. Correlation of serum concentrations of cystatin C and creatinine to inulin clearance in liver cirrhosis. Clin Chem 2000, 46(5):712-715.
37. Nasseri-Moghaddam S., Ganji M.-R., Kochari M.-R., Tofangchiha S. Serum cystatin-C is not superior to serum creatinine in predicting glomerular filtration rate in cirrhotic patients. Middle East J Dig Dis 2013, 5(4):209.
38. Larsson A., Malm J., Grubb A., Hansson L.O. Calculation of glomerular filtration rate expressed in mL/min from plasma cystatin C values in mg/L. Scand J Clin Lab Invest 2004, 64(1):25-30.
39. Xirouchakis E., Marelli L., Cholongitas E., et al. Comparison of cystatin C and creatinine-based glomerular filtration rate formulas with 51Cr-EDTA clearance in patients with cirrhosis. Clin J Am Soc Nephrol 2011, 6(1):84-92.
40. Inker L.A., Schmid C.H., Tighiouart H., et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012, 367(1):20-29.
41. Ladero J.M., Cárdenas M.C., Ortega L., et al. Serum cystatin C: a non-invasive marker of liver fibrosis or of current liver fibrogenesis in chronic hepatitis C?. Ann Hepatol 2012, 11(5):648-651.
42. Vivier P.-H., Storey P., Rusinek H., et al. Kidney function: glomerular filtration rate measurement with MR renography in patients with cirrhosis. Radiology 2011, 259(2):462-470.
43. Lee V.S., Rusinek H., Bokacheva L., et al. Renal function measurements from MR renography and a simplified multicompartmental model. Am J Physiol Renal Physiol 2007, 292(5):F1548-F1559.
44. Poreddy A.R., Neumann W.L., Freskos J.N., et al. Exogenous fluorescent tracer agents based on pegylated pyrazine dyes for real-time point-of-care measurement of glomerular filtration rate. Bioorg Med Chem 2012, 20(8):2490-2497.
45. Belcher J.M., Garcia-Tsao G., Sanyal A.J., et al. Association of AKI with mortality and complications in hospitalized patients with cirrhosis. Hepatology 2013, 57(2):753-762.
46. Belcher J.M., Sanyal A.J., Garcia-Tsao G., et al. Early trends in cystatin C and outcomes in patients with cirrhosis and acute kidney injury. Int J Nephrol 2014, 2014:1-8.
47. Kamath P.S., Wiesner R.H., Malinchoc M., et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001, 33(2):464-470.
48. Moylan C.A., Brady C.W., Johnson J.L., Smith A.D., Tuttle-Newhall J.E., Muir A.J. Disparities in liver transplantation before and after introduction of the meld score. JAMA 2008, 300(20):2371-2378.
49. Cholongitas E., Marelli L., Kerry A., et al. Female liver transplant recipients with the same GFR as male recipients have lower MELD scores-a systematic bias. Am J Transplant 2007, 7(3):685-692.
50. Davis C.L., Gonwa T.A., Wilkinson A.H. Identification of patients best suited for combined liver-kidney transplantation: part II. Liver Transpl 2002, 8(3):193-211.
51. Nadim M.K., Sung R.S., Davis C.L., et al. Simultaneous liver-kidney transplantation summit: current state and future directions. Am J Transplant 2012, 12(11):2901-2908.
52. Ruebner R., Goldberg D., Abt P.L., et al. Risk of end-stage renal disease among liver transplant recipients with pretransplant renal dysfunction. Am J Transplant 2012, 12(11):2958-2965.